At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 800 enrolled
Drug / intervention
Bimatoprost 0.01%drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Safety and Efficacy Study of Bimatoprost 0.01% in Primary Open-Angle Glaucoma (POAG) or Ocular Hypertension (OH)
In Brief
A Phase 4 clinical trial evaluating Bimatoprost 0.01% for Glaucoma, Open-Angle and Ocular Hypertension. Completed, enrolled 800 participants across 1 site.
Detailed Summary
This study will evaluate the safety and efficacy of bimatoprost 0.01% in subjects with elevated intraocular pressure (IOP) due to primary open-angle glaucoma (POAG) or ocular hypertension (OH).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlaucoma, Open-Angle, Ocular Hypertension
CountriesSouth Korea
Collaborators--
Timeline
Phase 4CompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartMar 2012
First PostedMay 2012
Primary CompletionJan 2013
TodayJul 2026
First PostedMay 9, 2012
Enrollment StartMar 1, 2012
Primary CompletionJan 1, 2013
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 14.1 years ago
Interventions
Bimatoprost 0.01%drug
1 drop in the affected eye(s), administered in the evening for 12 weeks.